Corrigendum: The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1250733/full |
_version_ | 1797782974709628928 |
---|---|
author | Zehao Zhao Zehao Zhao Zehao Zhao Shutong Dong Shutong Dong Shutong Dong Tienan Sun Tienan Sun Tienan Sun Kangning Han Kangning Han Kangning Han Xin Huang Xin Huang Xin Huang Meishi Ma Meishi Ma Meishi Ma Shiwei Yang Shiwei Yang Shiwei Yang Yujie Zhou Yujie Zhou Yujie Zhou |
author_facet | Zehao Zhao Zehao Zhao Zehao Zhao Shutong Dong Shutong Dong Shutong Dong Tienan Sun Tienan Sun Tienan Sun Kangning Han Kangning Han Kangning Han Xin Huang Xin Huang Xin Huang Meishi Ma Meishi Ma Meishi Ma Shiwei Yang Shiwei Yang Shiwei Yang Yujie Zhou Yujie Zhou Yujie Zhou |
author_sort | Zehao Zhao |
collection | DOAJ |
first_indexed | 2024-03-13T00:19:31Z |
format | Article |
id | doaj.art-960e1d96c7d74889b40db56637621276 |
institution | Directory Open Access Journal |
issn | 2297-055X |
language | English |
last_indexed | 2024-03-13T00:19:31Z |
publishDate | 2023-07-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Cardiovascular Medicine |
spelling | doaj.art-960e1d96c7d74889b40db566376212762023-07-11T17:01:25ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-07-011010.3389/fcvm.2023.12507331250733Corrigendum: The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapyZehao Zhao0Zehao Zhao1Zehao Zhao2Shutong Dong3Shutong Dong4Shutong Dong5Tienan Sun6Tienan Sun7Tienan Sun8Kangning Han9Kangning Han10Kangning Han11Xin Huang12Xin Huang13Xin Huang14Meishi Ma15Meishi Ma16Meishi Ma17Shiwei Yang18Shiwei Yang19Shiwei Yang20Yujie Zhou21Yujie Zhou22Yujie Zhou23Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, ChinaBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, ChinaBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, ChinaBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, ChinaBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, ChinaBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, ChinaBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, ChinaBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, ChinaDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, ChinaBeijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, ChinaBeijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, Chinahttps://www.frontiersin.org/articles/10.3389/fcvm.2023.1250733/fullfree fatty acids (FFA)coronary artery diseaseclopidogrelplatelet reactivitythromboelastogrampercutaneous coronary intervention |
spellingShingle | Zehao Zhao Zehao Zhao Zehao Zhao Shutong Dong Shutong Dong Shutong Dong Tienan Sun Tienan Sun Tienan Sun Kangning Han Kangning Han Kangning Han Xin Huang Xin Huang Xin Huang Meishi Ma Meishi Ma Meishi Ma Shiwei Yang Shiwei Yang Shiwei Yang Yujie Zhou Yujie Zhou Yujie Zhou Corrigendum: The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy Frontiers in Cardiovascular Medicine free fatty acids (FFA) coronary artery disease clopidogrel platelet reactivity thromboelastogram percutaneous coronary intervention |
title | Corrigendum: The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy |
title_full | Corrigendum: The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy |
title_fullStr | Corrigendum: The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy |
title_full_unstemmed | Corrigendum: The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy |
title_short | Corrigendum: The association between higher FFAs and high residual platelet reactivity among CAD patients receiving clopidogrel therapy |
title_sort | corrigendum the association between higher ffas and high residual platelet reactivity among cad patients receiving clopidogrel therapy |
topic | free fatty acids (FFA) coronary artery disease clopidogrel platelet reactivity thromboelastogram percutaneous coronary intervention |
url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1250733/full |
work_keys_str_mv | AT zehaozhao corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT zehaozhao corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT zehaozhao corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT shutongdong corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT shutongdong corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT shutongdong corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT tienansun corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT tienansun corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT tienansun corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT kangninghan corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT kangninghan corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT kangninghan corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT xinhuang corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT xinhuang corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT xinhuang corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT meishima corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT meishima corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT meishima corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT shiweiyang corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT shiweiyang corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT shiweiyang corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT yujiezhou corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT yujiezhou corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy AT yujiezhou corrigendumtheassociationbetweenhigherffasandhighresidualplateletreactivityamongcadpatientsreceivingclopidogreltherapy |